Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
25-valent pneumococcal conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Inventprise
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PF-07910630 is an investigational 25-valent pneumococcal conjugate vaccine (25vPnC) developed by Pfizer for the prevention of invasive pneumococcal disease and pneumonia caused by *Streptococcus pneumoniae*. As a fourth-generation conjugate vaccine, it expands upon the 20 serotypes included in Prevnar 20 (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) by incorporating five additional serotypes to provide broader protection against circulating strains. The vaccine utilizes Pfizer's proprietary conjugation technology, where capsular polysaccharides from each serotype are individually linked to the CRM197 carrier protein. This conjugation converts the polysaccharides into T-cell dependent antigens, enhancing the immune response and inducing long-term immunological memory. PF-07910630 is currently in Phase 2 clinical development, with trials evaluating its safety and immunogenicity in healthy adults compared to the current standard-of-care 20vPnC.
- Other names
- multivalent pneumococcal conjugate vaccinePfizer 25-valent pneumococcal conjugate vaccinePfizer25-valent pneumococcal conjugate vaccinePfizer-25-valent pneumococcal conjugate vaccinemultivalent pneumococcal conjugate vaccine-Pfizer-pneumococcal disease
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on 25-valent pneumococcal conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 25-valent pneumococcal conjugate vaccine.